title: Reply to letter: "Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)".
authors.affiliation: Department of Oncology, Haukeland University Hospital Bergen, Norway halfdan.sorbye@helse-bergen.no EORTC Headquarters, Statistics Department Brussels, Belgium Centre Hospitalier Universitaire Ambroise Paré Assistance Publique Hôpitaux de Paris Departments of Surgery and Oncology Boulogne-Billancourt, France.
authors.forename: Halfdan
authors.initials: H
authors.lastname: Sorbye
authors.forename: Murielle
authors.initials: M
authors.lastname: Mauer
authors.forename: Bernard
authors.initials: B
authors.lastname: Nordlinger
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D019990:Perioperative Care